AMGN Filing
4Filing Date: May 11, 2026

AMGEN INC (AMGN) · Insider Trading (Form 4) SEC Filing

Statement of Changes in Beneficial Ownership

descriptionView SEC Filing
ACC: 0000318154-26-000091open_in_new
Total Value$184.1K
Trades1
Insiders1

Transaction Details

REESE DAVID M
EVP & Chief Technology Officer·Direct
Tax W/H · Dispose
Common Stock
Shares-556
Price$331.11
Total Value$184.1K
Shares Owned After42.26K
Transaction DateMay 7, 2026
Footnotes ▸

These shares include 350 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Post-Transaction Holdings

REESE DAVID M
SecuritySharesChange
Common Stock42.26K-556 (-1.30%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-05-07 10b5-1 Pre-arranged Plan: No --- Issuer --- Name: AMGEN INC (AMGN) CIK: 0000318154 --- Reporting Owner --- Name: REESE DAVID M CIK: 0001748434 Role: Officer (EVP & Chief Technology Officer) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-05-07 | Code: F (Payment of exercise/tax) Shares: -556 | Price: $331.11 Total Value: $184,097.16 Shares Owned After: 42,256 | Ownership: D (Direct) Footnotes: [F1] These shares include 350 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. --- Footnotes (Complete Index) --- F1: These shares include 350 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount. --- Signature --- /s/ /s/ David M. Reese (2026-05-08)

keid analysis is for reference only and does not constitute investment advice.